Relay Therapeutics (RLAY) Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Goldman Sachs Reinstates Relay Therapeutics (RLAY) at Buy
September 9, 2024 4:47 PM EDTGoldman Sachs analyst Salveen Richter reinstates coverage on Relay Therapeutics (NASDAQ: RLAY) with a Buy rating and a price target of $20.00.
The analyst comments "Given positive Ph2 data of selective PI3K inhibitor RLY-2608 + fulvestrant in PI3K-mutated HR+/HER2- breast cancer and planned Ph3 initiation in 2025, we reinstate RLAY with a Buy rating and $20 price... More
TD Cowen Out Positive on Relay Therapeutics (RLAY), Shares Up ~53%, 'we are constructive on Ph3 success based on today's data'
September 9, 2024 3:20 PM EDTTD Cowen analyst Yaron Werber reiterated a Buy rating on Relay Therapeutics (NASDAQ: RLAY).
The analyst comments "Our Take: RLY-2608 Impresses With Unparalleled 9.2 Months mPFS, 33% ORR, And Minimal Hyperglycemia Moving into Ph3 Vs AZN Truqap This morning, Relay announced positive interim data for the RLY-2608 + fulvestrant doublet in HR+/HER2- locally advanced or metastatic breast cancer showing unmatched efficacy on PFS and ORR, and continued differentiation on safety vs both approved therapies (AZN's Truqap & NVS' Piqray). In our view, this data is highly encouraging and... More
Relay Therapeutics (RLAY) Shares Gain ~51%, PT Raised to $17 at Barclays
September 9, 2024 3:03 PM EDTBarclays analyst Peter Lawson raised the price target on Relay Therapeutics (NASDAQ: RLAY) to $17.00 (from $14.00) while maintaining a Overweight rating.
The analyst comments "We increase our probability of success for RLY-2608 in advanced HR+/HER2- breast cancer and increase our penetration rate... More
